DDInter379 DDInter1676
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cilostazol {u} (Compound) binds {v} (Gene) PDE3A
Cilostazol {u} (Compound) upregulates {v} (Gene) RRP8
Cilostazol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Cilostazol {u} (Compound) downregulates {v} (Gene) PPP2R5E
Cilostazol {u} (Compound) causes {v} (Side Effect) Arthritis
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Adenosine
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Cilostazol (Compound) binds PDE3A (Gene)
Cilostazol (Compound) upregulates RRP8 (Gene)
Cilostazol (Compound) palliates systemic scleroderma (Disease)
Cilostazol (Compound) downregulates PPP2R5E (Gene)
Cilostazol (Compound) causes Arthritis (Side Effect)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Cilostazol may lead to a major life threatening interaction when taken with Fondaparinux